Untitled

doi:10.18632/oncotarget.v8i45

Cited by 11 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a similar retrospective study by Ferrucci et al. ( 38 ), a relative eosinophil count ≥ 1.5% was associated with a favorable outcome in patients receiving anti-CTLA4. However, in other studies, the baseline eosinophil count was not associated with OS ( 33 , 42 ).…”

Section: Resultsmentioning

confidence: 71%

See 1 more Smart Citation

Eosinophilic granulocytes as a potential prognostic marker for cancer progression and therapeutic response in malignant melanoma

Brand,

Hunger,

Seyed Jafari

2024

Front. Oncol.

View full text Add to dashboard Cite

The importance of eosinophilic granulocytes in cancer has been widely discussed in recent years. The current study reviews the evidence on the role of eosinophilic granulocytes in melanoma as a prognostic marker for cancer progression and the efficacy of treatment with modern immune checkpoint inhibitors. A total of 33 human clinical studies were included in the review, with heterogeneous data due to differences in patients populations, study design and inclusion of small study groups. However, 28 of the 33 studies suggested that eosinophilic granulocytes could be used as a prognostic biomarker for outcome and/or potential response to systemic treatment and/or occurrence of adverse events in melanoma patients. Nevertheless, the exact role of eosinophils remains to be elucidated. Further prospective, larger and better controlled studies are warranted to clarify the significance of eosinophilic granulocytes in patients with melanoma, in more details.

show abstract

Section: Resultsmentioning

confidence: 71%

“…Ferrucci et al. ( 38 ) showed that EC in patients underwent chemotherapy was not associated with PFS or OS in patients with advanced melanoma.…”

Section: Resultsmentioning

confidence: 99%

Eosinophilic granulocytes as a potential prognostic marker for cancer progression and therapeutic response in malignant melanoma

Brand,

Hunger,

Seyed Jafari

2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…How it is associated with COAD is not clear. Possible mechanism involves its cation channel feature, as tumor microenvironment is often acidic due to the active glycolysis ( 72 ). Overall, this 6-gene model is effective in COAD prognosis.…”

Section: Discussionmentioning

confidence: 99%

PANoptosis-related genes function as efficient prognostic biomarkers in colon adenocarcinoma

Liu,

Wang,

Feng

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundPANoptosis is a newly discovered cell death type, and tightly associated with immune system activities. To date, the mechanism, regulation and application of PANoptosis in tumor is largely unknown. Our aim is to explore the prognostic value of PANoptosis-related genes in colon adenocarcinoma (COAD).MethodsAnalyzing data from The Cancer Genome Atlas-COAD (TCGA-COAD) involving 458 COAD cases, we concentrated on five PANoptosis pathways from the Molecular Signatures Database (MSigDB) and a comprehensive set of immune-related genes. Our approach involved identifying distinct genetic COAD subtype clusters and developing a prognostic model based on these parameters.ResultsThe research successfully identified two genetic subtype clusters in COAD, marked by distinct profiles in PANoptosis pathways and immune-related gene expression. A prognostic model, incorporating these findings, demonstrated significant predictive power for survival outcomes, underscoring the interplay between PANoptosis and immune responses in COAD.ConclusionThis study enhances our understanding of COAD’s genetic framework, emphasizing the synergy between cell death pathways and the immune system. The development of a prognostic model based on these insights offers a promising tool for personalized treatment strategies. Future research should focus on validating and refining this model in clinical settings to optimize therapeutic interventions in COAD.

show abstract

“…Transcatheter arterial chemoembolization (TACE) is the first-line therapy for intermediate-stage HCC and has been extensively used to treat unresectable HCC (uHCC) in China ( 9 ), though HCC with PVTT is considered a contraindication for TACE ( 10 ). However, several recent studies reported that patients with good hepatic function and sufficient collateral circulation around the thrombus may tolerate and benefit from TACE ( 11 – 13 ).…”

Section: Introductionmentioning

confidence: 99%

Case report: Complete response after transcatheter arterial chemoembolization combined with donafenib plus tislelizumab therapy for hepatocellular carcinoma with main trunk portal vein tumor thrombus in a patient coinfected with HIV and HBV

Xiao,

Fu,

Qin

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

BackgroundCoinfection with the human immunodeficiency virus (HIV) and the hepatitis B virus (HBV) occurs in 5–67% of patients with HIV. HIV weakens the human immune system and leads to various tumors. Patients with unresectable hepatocellular carcinoma (HCC) and HIV experience poor treatment efficacy and have a short survival period. Approximately 70% of cases of HCC are diagnosed at advanced stages due to the subtle onset of the disease. As a result, most cases are not suits for curative therapy. Transcatheter arterial chemoembolization (TACE) is the first-line treatment for intermediate-stage HCC and is commonly used to treat unresectable HCC in China. Recent advancements in systemic treatments have significantly enhanced the effectiveness of unresectable HCC treatment. Several previous study showed that combination treatment combination therapy can enhance the efficacy. Notably, studies proposed that TACE combined targeted drugs with immune checkpoint inhibitors results in a high objective response rate and overall survival. However, the novelty of this study lies in its report of a complete response using a triple combination in patients with HIV and HCC with main trunk portal vein tumor thrombus.Case presentationA 57-year-old woman was diagnosed with HCC with a main trunk portal vein tumor thrombus combined with HIV infection, cirrhosis, and chronic viral hepatitis. She underwent TACE and was administered donafenib and tislelizumab. This triple therapy treatment regimen resulted in a clinical complete response according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) based on contrast-enhanced computed tomography.ConclusionWe first used TACE combined with donafenib and tislelizumab for HCC patients with main trunk portal vein tumor thrombus and HIV-HBV coinfection and achieved complete response.

show abstract

Untitled

Cited by 11 publications

References 3 publications

Eosinophilic granulocytes as a potential prognostic marker for cancer progression and therapeutic response in malignant melanoma

Eosinophilic granulocytes as a potential prognostic marker for cancer progression and therapeutic response in malignant melanoma

PANoptosis-related genes function as efficient prognostic biomarkers in colon adenocarcinoma

Case report: Complete response after transcatheter arterial chemoembolization combined with donafenib plus tislelizumab therapy for hepatocellular carcinoma with main trunk portal vein tumor thrombus in a patient coinfected with HIV and HBV

Contact Info

Product

Resources

About